Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 1508.

https://doi.org/10.1182/blood.V120.21.1508.1508

Published: 2012

Journal Articles

CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

Jeffrey E Lancet, MD, Jorge E Cortes, MD, Tibor Kovacsovics, MD, Donna E. Hogge, MD, PhD, FRCPC, Jonathan E. Kolitz, MD, Martin S Tallman, MD, Antje Hoering, PhD, Michael T. Chiarella, Arthur C. Louie, MD, Eric Feldman, MD

Blood (2012) 120 (21): 3626.

https://doi.org/10.1182/blood.V120.21.3626.3626

Published: 2012

Journal Articles

Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

Blood (2012) 120 (21): 414.

https://doi.org/10.1182/blood.V120.21.414.414

Published: 2012

Journal Articles

A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.

Jorge Cortes, MD, Gail J. Roboz, MD, Hagop Kantarjian, MD, Eric Feldman, MD, Judy Karp, MD, Allyson Pollack, Katrina Sandy, RN, Niranjan Rao, Shiro Akinaga, Mark Levis, MD

Blood (2007) 110 (11): 909.

https://doi.org/10.1182/blood.V110.11.909.909

Published: 2007

Journal Articles

PTK787/ZK 222584 (PTK/ZK), an Oral Tyrosine Kinase Inhibitor, Has Activity in Patients with Agnogenic Myeloid Metaplasia (AMM).

Francis J. Giles, MD, Michael Carroll, MD, Alan List, MD, Alessandra Ferrajoli, MD, Deborah Thomas, MD, Jorge Cortes, MD, Eric Feldman, MD, Gail Roboz, MD

Blood (2006) 108 (11): 4920.

https://doi.org/10.1182/blood.V108.11.4920.4920

Published: 2006

Journal Articles

Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

Ellen Ritchie, MD, Lia Gore, MD, Gail J. Roboz, MD, Eric Feldman, MD, Farhad Ravandi, MD, Richard Furman, MD

Blood (2006) 108 (11): 1881.

https://doi.org/10.1182/blood.V108.11.1881.1881

Published: 2006

Journal Articles

Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

Jia Ruan, MD, PhD, Morton Coleman, MD, Richard R. Furman, MD, Patricia Glynn, Maureen Joyce, Jamie Ketas, Ken Cheung, PhD, Sarah Church, Tsiporah Shore, MD, Eric Feldman, MD, Sarah Rutherford, Elizabeth Hyjek, MD, PhD, Amy Chadburn, MD, Shahin Rafii, MD, John P. Leonard, MD

Blood (2006) 108 (11): 2751.

https://doi.org/10.1182/blood.V108.11.2751.2751

Published: 2006

Journal Articles

High-Dose Mitoxantrone-Based Induction Therapy in Newly-Diagnosed AML. Results of 171 Patients Treated at NYMC between 1991–2003.

Karen Seiter, MD, Delong Liu, MD, PhD, Eric Feldman, MD, Qiuhu Shi, PhD, Paul Baskind, Muhammad Arshad, MD, Anila Qureshi, MD, Tauseef Ahmed, MD

Blood (2005) 106 (11): 1859.

https://doi.org/10.1182/blood.V106.11.1859.1859

Published: 2005

Journal Articles

A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.

David A. Rizzieri, MD, Eric Feldman, MD, Joseph O. Moore, MD, Gail J. Roboz, MD, John F. DiPersio, MD, Nashat Gabrail, MD, Wendy Stock, MD, Victor M. Rivera, PhD, Maher Albitar, MD, Camille L. Bedrosian, MD, Francis Giles, MD

Blood (2005) 106 (11): 2980.

https://doi.org/10.1182/blood.V106.11.2980.2980

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.

PTK787/ZK 222584 (PTK/ZK), an Oral Tyrosine Kinase Inhibitor, Has Activity in Patients with Agnogenic Myeloid Metaplasia (AMM).

Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

High-Dose Mitoxantrone-Based Induction Therapy in Newly-Diagnosed AML. Results of 171 Patients Treated at NYMC between 1991–2003.

A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only